Digibus (c): results from the first self-driving shuttle trial on a public road in Austria

被引:33
|
作者
Rehrl, Karl [1 ]
Zankl, Cornelia [1 ]
机构
[1] Salzburg Res Forsch Gesellsch mbH, Jakob Haringer Str 5, A-5020 Salzburg, Austria
关键词
Automated driving; Self-driving shuttle; Public road trial; Rural area; First/last mile;
D O I
10.1186/s12544-018-0326-4
中图分类号
U [交通运输];
学科分类号
08 ; 0823 ;
摘要
From April to November 2017, the non-profit research organisation Salzburg Research conducted the "Digibus (c) 2017" trial, the first trial of a self-driving shuttle on a public road in Austria. The shuttle from the French company Navya Tech has been tested on a 1.4-km long track in the village of Koppl, which is situated approximately ten kilometres east from the City of Salzburg. The trial in Koppl was one of the first trials worldwide on public roads with mixed traffic in a rural area. The focus of this trial was on the real-world evaluation of a self-driving shuttle for bridging the first/last mile in public transport. From April to November 2017, 240 test drives with 874 passengers covering 341 test kilometres have been conducted. Results show that the technology is ready for testing, but there is still a long way to go for driverless operation, especially in mixed traffic scenarios. The work describes the trial setting, the test route, the process of deploying the shuttle, experiences collected during the trial as well as results from a passenger survey. The accompanying passenger survey with 294 participants revealed high acceptance and a good feeling of safety.
引用
收藏
页数:11
相关论文
共 45 条
  • [31] Mature results from Hoosier Oncology Group GU04-75 phase II trial of cisplatin (C), gemcitabine (G), and bevacizumab (B) as first-line chemotherapy for metastatic urothelial carcinoma (UC)
    Hahn, N. M.
    Stadler, W. M.
    Zon, R.
    Waterhouse, D. M.
    Picus, J.
    Nattam, S. R.
    Johnson, C. S.
    Perkins, S. M.
    Waddell, M. J.
    Sweeney, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [32] Updated results from the multicenter phase II, ALTER-C001 trial: Efficacy and safety of anlotinib plus XELOX regimen as first-line treatment followed by maintenance monotherapy of anlotinib for patients with mCRC
    Jin, Y.
    Han, Y.
    Zhang, L.
    Jin, Y.
    Sun, H.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S720 - S721
  • [33] Blockade of HLA Antibody-Triggered Classical Complement Activation in Sera From Subjects Dosed With the Anti-C1s Monoclonal Antibody TNT009-Results from a Randomized First-in-Human Phase 1 Trial
    Muehlbacher, Jakob
    Jilma, Bernd
    Wahrmann, Markus
    Bartko, Johann
    Eskandary, Farsad
    Schoergenhofer, Christian
    Schwameis, Michael
    Parry, Graham C.
    Gilbert, James C.
    Panicker, Sandip
    Boehmig, Georg A.
    TRANSPLANTATION, 2017, 101 (10) : 2410 - 2418
  • [34] Adding Mercaptopurine and Methotrexate to Alternate Week ATRA Maintenance Therapy Does Not Improve the Outcome for Adults with Acute Promyelocytic Leukemia (APL) in First Remission: Results From North American Leukemia Intergroup Trial C9710
    Powell, Bayard L.
    Moser, Barry K.
    Stock, Wendy
    Gallagher, Robert E.
    Willman, Cheryl L.
    Stone, Richard M.
    Rowe, Jacob M.
    Coutre, Steven E.
    Feusner, James H.
    Gregory, John
    Couban, Stephen
    Appelbaum, Frederick R.
    Tallman, Martin S.
    Larson, Richard A.
    BLOOD, 2011, 118 (21) : 118 - 119
  • [35] VP10-2021: Cabozantinib (C) plus atezolizumab (A) versus sorafenib (S) as first-line systemic treatment for advanced hepatocellular carcinoma (aHCC): Results from the randomized phase III COSMIC-312 trial
    Kelley, R. K.
    Yau, T.
    Cheng, A. -L.
    Kaseb, A.
    Qin, S.
    Zhu, A. X.
    Chan, S.
    Sukeepaisarnjaroen, W.
    Breder, V.
    Verset, G.
    Gane, E.
    Borbath, I.
    Rangel, J. D. Gomez
    Merle, P.
    Benzaghou, F. M.
    Banerjee, K.
    Hazra, S.
    Fawcett, J.
    Rimassa, L.
    ANNALS OF ONCOLOGY, 2022, 33 (01) : 114 - 116
  • [36] Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multicenter phase II trial ALTER-G-001-cohort C
    Wu, J.
    Zhou, C.
    Yan, J.
    Han, Z.
    Wang, C.
    Qin, Z.
    Jiang, J.
    Wang, C.
    Tang, X.
    Zhu, L.
    Chen, J.
    Mao, Y.
    Wei, X.
    Shangguan, C.
    Zhang, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S1533 - S1533
  • [37] Anlotinib plus chemotherapy as first-line therapy for patients with gastrointestinal tumor with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial, ALTER-G-001-cohort C
    Wu, Junwei
    Zhou, Chenfei
    Yan, Jun
    Han, Zhengxiang
    Wang, Chun
    Qin, Zhiquan
    Jiang, Jinling
    Wang, Chunbing
    Tang, Xinyu
    Zhu, Lingjun
    Chen, Jun
    Mao, Yong
    Zhu, Liangjun
    Wei, Xiaowei
    Shangguan, Chengfang
    Zhang, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [38] Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort C
    Wu, Junwei
    Zhou, Chenfei
    Yan, Jun
    Han, Zhengxiang
    Wang, Chun
    Qin, Zhiquan
    Jiang, Jinling
    Wang, Chunbin
    Tang, Xinyu
    Zhu, Lingjun
    Chen, Jun
    Mao, Yong
    Wei, Xiaowei
    Shangguan, Chengfang
    Zhang, Jun
    CANCER RESEARCH, 2024, 84 (07)
  • [39] BEAT-meso: A randomized phase III study of bevacizumab (B) and standard chemotherapy (C) with or without atezolizumab (A), as first-line treatment (TX) for advanced pleural mesothelioma (PM)-Results from the ETOP 13-18 trial.
    Popat, Sanjay
    Felip, Enriqueta
    Dafni, Urania
    Pope, Anthony
    Perez, Susana Cedres
    Shah, Riyaz N. H.
    de Marinis, Filippo
    Smith, Laura Cove
    Caro, Reyes Bernabe
    Frueh, Martin
    Nackaerts, Kristiaan
    Greillier, Laurent
    Scherz, Amina
    Massuti, Bartomeu
    Schaer, Saemi
    Prince, Spasenija Savic
    Roschitzki-Voser, Heidi
    Ruepp, Barbara
    Peters, Solange
    Stahel, Rolf A.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17_SUPPL) : LBA8002 - LBA8002
  • [40] Pevonedistat (MLN4924), an Investigational, First-in-Class NAE Inhibitor, in Combination with Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML) Considered Unfit for Conventional Chemotherapy: Updated Results from the Phase 1 C15009 Trial
    Swords, Ronan T.
    Savona, Michael R.
    Maris, Michael B.
    Erba, Harry P.
    Berdeja, Jesus G.
    Foran, James M.
    Hua, Zhaowei
    Faessel, Helene M.
    Dash, Ajeeta B.
    Sedarati, Farhad
    Dezube, Bruce J.
    Medeiros, Bruno C.
    BLOOD, 2014, 124 (21)